Authors:
de la Serna, FA
Tolleson, TR
Crowley, JJ
Stack, RS
Zidar, JP
Citation: Fa. De La Serna et al., Intra-arterial thrombolysis (reteplase) and reopro for subacute thrombosisof the distal aorta accomplished by radial arterial access: The radial-kissing-thrombolytic technique, CATHET C IN, 53(2), 2001, pp. 264-268
Authors:
Kelly, K
Lovato, L
Bunn, PA
Livingston, RB
Zangmeister, J
Taylor, SA
Roychowdhury, D
Crowley, JJ
Gandara, DR
Citation: K. Kelly et al., Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: A phase II trial of the southwest oncology group, CLIN CANC R, 7(8), 2001, pp. 2325-2329
Authors:
Hoque, A
Albanes, D
Lippman, SM
Spitz, MR
Taylor, PR
Klein, EA
Thompson, IM
Goodman, P
Stanford, JL
Crowley, JJ
Coltman, CA
Santella, RM
Citation: A. Hoque et al., Molecular epidemiologic studies within the selenium and vitamin e cancer prevention trial (SELECT), CANC CAUSE, 12(7), 2001, pp. 627-633
Authors:
Thomas, CR
Giroux, DJ
Janaki, LM
Turrisi, AT
Crowley, JJ
Taylor, SA
McCracken, JD
Giri, PGS
Gordon, W
Livingston, RB
Gandara, DR
Citation: Cr. Thomas et al., Ten-year follow-up of Southwest Oncology Group 8269: a phase II trial of concomitant cisplatin - etoposide and daily thoracic radiotherapy in limitedsmall-cell lung cancer, LUNG CANC, 33(2-3), 2001, pp. 213-219
Authors:
Dhodapkar, MV
Jacobson, JL
Gertz, MA
Rivkin, SE
Roodman, GD
Tuscano, JM
Shurafa, M
Kyle, RA
Crowley, JJ
Barlogie, B
Citation: Mv. Dhodapkar et al., Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003), BLOOD, 98(1), 2001, pp. 41-48
Citation: R. Mick et al., Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint, CONTR CL TR, 21(4), 2000, pp. 343-359
Authors:
Pisters, KMW
Ginsberg, RJ
Giroux, DJ
Putnam, JB
Kris, MG
Johnson, DH
Roberts, JR
Mault, J
Crowley, JJ
Bunn, PA
Citation: Kmw. Pisters et al., Induction chemotherapy before surgery for early-stage lung cancer: A novelapproach, J THOR SURG, 119(3), 2000, pp. 429-437
Citation: Kr. Kruse et al., Local drug delivery of argatroban from a polymeric-metallic composite stent reduces platelet deposition in a swine coronary model, CATHET C IN, 46(4), 1999, pp. 503-507
Authors:
Hesketh, PJ
Crowley, JJ
Burris, HA
Williamson, SK
Balcerzak, SP
Peereboom, D
Goodwin, JW
Gross, HM
Moore, DF
Livingston, RB
Gandara, DR
Citation: Pj. Hesketh et al., Evaluation of docetaxel in previously untreated extensive-stage small celllung cancer: A Southwest Oncology Group phase II trial, CA J SCI AM, 5(4), 1999, pp. 237-241
Authors:
Vesole, DH
Crowley, JJ
Catchatourian, R
Stiff, PJ
Johnson, DB
Cromer, J
Salmon, SE
Barlogie, B
Citation: Dh. Vesole et al., High-dose melphalan with autotransplantation for refractory multiple myeloma: Results of a southwest oncology group phase II trial, J CL ONCOL, 17(7), 1999, pp. 2173-2179
Authors:
Harcombe, AA
Ludman, PF
Wisbey, C
Crowley, JJ
Sharples, L
Shapiro, LM
Citation: Aa. Harcombe et al., Balloon mitral valvuloplasty: comparison of haemodynamic and echocardiographic assessment of mitral stenosis at different heart rates in the catheterisation laboratory, INT J CARD, 68(3), 1999, pp. 253-259
Authors:
Wakshull, E
Brunke-Reese, D
Lindermuth, J
Fisette, L
Nathans, RS
Crowley, JJ
Tufts, JC
Zimmerman, J
Mackin, W
Adams, DS
Citation: E. Wakshull et al., PGG-Glucan, a soluble beta-(1,3)-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-kappa B-like factor in human PMN: Evidence for a glycosphingolipid beta-(1,3)-glucan receptor, IMMUNOPHARM, 41(2), 1999, pp. 89-107
Authors:
Hutchins, LF
Unger, JM
Crowley, JJ
Coltman, CA
Albain, KS
Citation: Lf. Hutchins et al., Underrepresentation of patients 65 years of age or older in cancer-treatment trials., N ENG J MED, 341(27), 1999, pp. 2061-2067